SCMOM 2012_Capricor
Capricor #39;s cardiac-derived stem cells (CDCs) represent a novel treatment to repair the heart after muscle loss following large heart attacks. This is accomplished through the regeneration of heart muscle and the shrinking of scar tissue. The CADUCEUS trial, which utilized Capricor #39;s CDCs, showed an approximate 50% reduction of scar size and 50% more viable heart muscle one-year post heart attack. This fall, Capricor plans to begin enrollment of ALLSTAR, a Phase I/II FDA approved study using allogeneic CDCs to treat patients 30-days to 1-year after a large heart attack. The goal is to show a relative reduction in scar tissue. http://www.capricor.com Presenter: Linda Marbán, Ph.D., CEO, CapricorFrom:AllianceRegenMedViews:2 1ratingsTime:21:12More inScience Technology
Continue reading here:
SCMOM 2012_Capricor - Video